



**HBD EAST 2023**

**CURRENT SITUATION:  
MEDICAL DEVICE REGULATIONS  
OUTSIDE OF JAPAN AND THE US**


Kate Stohlman



# MEDICAL DEVICES

## Recent Updates

- European Union
- Canada
- Australia
- South America
- China
- India



# EUROPEAN UNION


A bit of a moving target....

## Switzerland

- SW now accepting market clearance applications from FDA-approved devices as well as CE Marked devices

## United Kingdom

- BREXIT happened
- UKCA requesting certification to the UK MDR 2002 / 2019
  - More work/\$ for Notified Bodies
  - Additional symbol on labels
  - Additional Authorized Representative = UKRP



# EUROPEAN UNION

## Progress towards implementation of the EU Medical Device Regulation (EU MDR)

- **Capacity constraints** with Notified Bodies (NB) due to fewer NBs, new NB training and certifications, new internal procedures development
  - 38 Notified Bodies
  - 43% increased work per certificate
  - 18 months average time QMS + Device
  - 85% of Tech Dossiers incomplete
- **Therapy Effectiveness** now reviewed - 100% of medical devices need complete reviews
  - Not every NB has "scope"

- **17,000 Certificates expire in 2024**
  - Many NBs refusing new applications
  - Most NBs refusing new customers
  - Certificates, Applications, and Refused Applications, on the rise....
  - Legacy MDD Class III devices now have until 2027-12 to transition to the MDR

## Technical File

- Clinical Evaluation Process, PMS
- New Labeling Requirements, UDI

## Quality Management Systems



- EU MDR doubles the on-site QMS inspection subjects vs. ISO13483(2016)



# EUROPEAN UNION

**June 2023**  
**MDR Applications: 13.177**  
**MDR Certificates: 3.899**

## Applications



# CANADA – HEALTH CANADA

## Market Clearance

- Many proposed amendments in review
- Multiple new draft guidances in development
  - Machine Learning & SaMD
  - Establishment Licensing
  - Device Classification
  - Agility for Emergencies
- eSTAR (electronic submission) pilot fully enrolled 2023-10-31
  - FDA joint applications & CA only
  - IMDRF Medical Device Table of Contents

## Quality System

- **MDSAP** is alive and well and living in Canada, Brazil, Australia, Japan & USA
  - **MDSAP ISO 13485 (2016)** Certificate before Market Access as of 2019-01, *no more CMDCAS*
  - 13 Recognized providers
  - All Health Canada registrars are now authorized to perform Medical Device Single Audit Program audits

# AUSTRALIA – TGA – THERAPEUTIC GOODS ADMINISTRATION

## Market Clearance

- Comply with AUS MDR 2002
  - Essential Principals - Conformity
- TGA Application + Audit
  - Audit reduced with FDA PMA or EU-MDR Market Authorization
- ARG MD Update 2023-11-02
  - Additional recognition for EU-MDR Device & QMS certs
  - EU Device Codes & AE reports
  - Revised Market Access checklist
- Transparent process but complex


## Revised Guidances

- Conformity Assessment application
- Software as a Medical Device
- Adverse Event reports
- Off-label use of Medical Devices
- Auditing of Medical Devices
- Device classification

## Quality Systems – *Get a Certificate*

- See the Essential Principals Checklist
  - Risk Management
  - Biocompatibility
  - Clinical Evidence

## Flowchart Describing the AUS TGA application process for Conformity Certification





# LATIN AMERICA – THEY'RE ALL A LITTLE DIFFERENT

## Brazil - ANVISA

- Very large market, 214M people
- *Member of MDSAP, IMDRF*
- High Risk Device requires registration
  - Tech File with expert assessment
  - Attention to measurement & electronics
  - Revalidation @ 10 yrs
  - Brazil GMP Certification

## Columbia - INVIMA

- Large market, 51M people
- Local Representative
- QMS – GMP
- Application with Columbia-specific format

## Mexico – COFEPRIS

- Very large market, 127M people
- Leverage Health Canada or FDA approval
- Import permit required for implantables
- *New regulations for Nano Materials & SaMD*
- QMS - ISO 13485 Certification required

## Argentina - ANMAT

- Large market, 45M people
- Authorized Representative required
- Home Country Approval
- Essential Requirements Checklist
- QMS – GMP aligned with ANMAT
- Adverse event reporting

# CHINA – AIMING FOR GLOBAL CLINICAL LEADERSHIP

## Market Clearance - NMPA

- Since 2017, emphasis on lifecycle management
- International harmonization
  - Product registration dossier
  - Clinical data / evidence requirements
- Pathways to registration:
  - “on the exempt list”
  - Class II and III (like PMA products) CER
  - Overseas data accepted – if ethical, legal & scientific
  - Real-world data (2019)
  - Clinical Trials


## Investments in Transparency

- Exempt List – 1000 medical devices
  - Mechanism of action – clear
  - Design & production – mature
  - No/low SAEs
  - Safe & effective with existing data support
- Technical Review – Chinese standards
  - Multiple observation endpoints
  - GMP

## Real-world Data

- HaiNan Province RWD Zone Pilot 2018
- Published RWD guidance document

# CHINA – PATHWAYS TO NMPA REGISTRATION



**FIGURE** Key clinical pathways and decision tree for device registrations with the China National Medical Products Administration.<sup>9</sup>

# INDIA – ALL MEDICAL DEVICES “SOON TO BE FULLY REGULATED”

## Market Clearance - CDSCO

- 2023-10-01 - Devices of all classification need a license
  - Technical Dossier
    - device master record
    - factory file (GMP)
    - technical presentation
    - a 9-month review process.
  - Apply to DCGI prior to registration
  - Or get a “No Objective Certificate”
  - Local agent required.
- Draft regulations for **device classification**
    - Class A & B import license with country of origin approval
    - Class B, C, & D *require clinical data*
    - Class D – High Risk (heart valves and other implantables)

# CONCLUSIONS – SMALL COMPANY POINT OF VIEW

## Common Issues

- Regulations are proliferating faster than harmonization as countries gain economic strength & need for medical devices
- Difficult to know all regional specifics in countries of commercial interest
- Fast Growth in post-market surveillance expectations – *but no one wants to pay for registries & infrastructure*
  - Patient Tokens?

## Company Efficiencies

- More use of consultants & part time work
  - Stop growing the company head count
  - Provides access to regional specialists
  - Work-from-home technologies enable qualified specialists available off-site
- More emphasis on Matrix Management
  - Therapy specialists
  - Regional specialists
  - Surveillance specialists
- More use of information management systems



